Blog Archive
-
▼
2008
(79)
-
▼
September
(6)
- Memory Pharmaceuticals : Phase 1 Multiple Ascendin...
- Baxter : Phase III Trial for the Treatment of Alzh...
- Xel Pharmaceuticals : Successful Completion of Pro...
- Memory Pharmaceuticals and Roche : R3487/MEM 3454 ...
- AstraZeneca and Targacept : top-line results from ...
- Pfizer and Medivation : Global Agreement to Co-De...
-
▼
September
(6)
Thursday, September 18, 2008
Xel Pharmaceuticals : Successful Completion of Prototype Once-A-Week Huperzine A Transdermal Patch for Alzheimer's Disease
September 10, 2008 — Xel Pharmaceuticals, Inc. announced the completion of the development of its once-a-week Huperzine A transdermal patch for the treatment of Alzheimer's Disease (AD). The prototype transdermal patch can deliver 400–800 mcg of Huperzine A per day for up to seven days. Huperzine A is a naturally occurring alkaloid found from the club moss Huperzia serrata that has been used for decades in China as a prescription medication for the treatment of dementia. Huperzine A is a potent, highly selective and reversible inhibitor of acetyl cholinesterase. Additionally, Huperzine A has anti-oxidative properties and possesses neuro-protective properties against glutamate that induce neuronal toxicity at the N-methyl-D-aspartate (NMDA) receptor... Xel Pharmaceuticals' Press Release -